Journal Article
. 2020 Nov;10().
doi: 10.3389/fonc.2020.01583.

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database

Ran Cheng 1 Xiangyi Kong 1 Xiangyu Wang 1 Yi Fang 1 Jing Wang 1 
  • PMID: 33194568
  •     29 References


Objective: To explore the distribution of Oncotype DX Breast Recurrence Score (RS), the proportion of receiving chemotherapy, and the relationship between RS and chemotherapy benefit according to detailed age groups in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-negative (HR+/HER2-/N0) breast cancer. Methods: This was an extensive, comprehensive, population-based retrospective study. Data on individuals with breast cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program. The cohort was divided into five groups by age (≤ 35, 36-50, 51-65, 66-80, >80 years). RS distribution and chemotherapy proportion among different age groups were analyzed, and the overall survivals between patients receiving chemotherapy and those not/unknown were compared in each age group. Results: The study cohort comprised 49,539 patients and the largest age group was 51-65 years. The percentage of patients with low-risk RS (0-10) increased with age, whereas those with intermediate-risk RS (11-25) decreased with age (except for the group of 36-50 years, which had the highest rate of intermediate-risk RS). The age group ≤35 years has the greatest rate of high-risk RS (26-100). The proportion of receiving chemotherapy decreased with age in all RS risk categories. Overall survival was benefited by chemotherapy only in the age group of 66-80 years with intermediate- and high-risk RS, and chemotherapy seemed to do more harm than good for patients older than 80 years. Conclusions: In the present study, we identified the distribution of RS, the proportion of receiving chemotherapy, and the relationship between RS and chemotherapy benefit according to a detailed age grouping for women with HR+/HER2-/N0 breast cancer, which may help in making individualized clinical decisions.

Keywords: HR+/HER2–/N0 breast cancer; Oncotype DX breast recurrence score; SEER database; chemotherapy benefit; detailed age grouping.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Charles E Geyer, Gong Tang, +8 authors, Norman Wolmark.
NPJ Breast Cancer, 2018 Nov 21; 4. PMID: 30456299    Free PMC article.
Precision medicine in breast cancer: reality or utopia?
Ali Bettaieb, Catherine Paul, +3 authors, François Ghiringhelli.
J Transl Med, 2017 Jun 19; 15(1). PMID: 28623955    Free PMC article.
Limitations and biases of the Surveillance, Epidemiology, and End Results database.
Henry S Park, Shane Lloyd, +2 authors, James B Yu.
Curr Probl Cancer, 2012 Apr 07; 36(4). PMID: 22481009
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Self-detection remains a key method of breast cancer detection for U.S. women.
Mara Y Roth, Joann G Elmore, +3 authors, Diana L Miglioretti.
J Womens Health (Larchmt), 2011 Jun 17; 20(8). PMID: 21675875    Free PMC article.
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019).
Michael Untch, Christoph Thomssen, +21 authors, Nadia Harbeck.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217628    Free PMC article.
Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.
Cesar Augusto Santa-Maria, Melissa Camp, +3 authors, Vered Stearns.
Oncology (Williston Park), 2015 Nov 18; 29(11). PMID: 26573062
Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Sylvia A Reyes, Lucy M De La Cruz, +2 authors, Elisa Port.
Ann Surg Oncol, 2019 Aug 21; 26(10). PMID: 31429016
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, +26 authors, George W Sledge.
JAMA Oncol, 2019 Oct 01; 6(3). PMID: 31566680    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Lu Zhang, Mei-Chin Hsieh, +3 authors, Xiao-Cheng Wu.
Breast Cancer Res Treat, 2020 Feb 16; 180(2). PMID: 32060781
The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.
Máire A Duggan, William F Anderson, +2 authors, Mark E Sherman.
Am J Surg Pathol, 2016 Oct 16; 40(12). PMID: 27740970    Free PMC article.
Highly Cited. Review.
Breast Cancer Is Our Global Responsibility.
Nadia Harbeck, Michael Gnant, Christoph Thomssen.
Breast Care (Basel), 2016 Mar 19; 10(6). PMID: 26989353    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Sexual quality of life evaluation after treatment among women with breast cancer under 35 years old.
Anaïse Blouet, Marie Zinger, +4 authors, Yoann Pointreau.
Support Care Cancer, 2018 Aug 18; 27(3). PMID: 30116944
How generalizable are the SEER registries to the cancer populations of the USA?
Tzy-Mey Kuo, Lee R Mobley.
Cancer Causes Control, 2016 Jul 23; 27(9). PMID: 27443170    Free PMC article.
Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Kai-Hua Liu, Lei Zhang, +4 authors, San-Gang Wu.
Breast, 2020 Jan 10; 49. PMID: 31918322    Free PMC article.
Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.
Patricia Tai, Edward Yu, +2 authors, Georges Vlastos.
BMC Cancer, 2004 Sep 04; 4. PMID: 15345027    Free PMC article.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Philip D Poorvu, Shari I Gelber, +12 authors, Ann H Partridge.
J Clin Oncol, 2019 Dec 07; 38(7). PMID: 31809240    Free PMC article.
Breast Cancer in Women Older Than 80 Years.
Shlomit Strulov Shachar, Arti Hurria, Hyman B Muss.
J Oncol Pract, 2016 Feb 13; 12(2). PMID: 26869650
Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study.
Alison Pearce, Marion Haas, +4 authors, Robyn Ward.
PLoS One, 2017 Oct 11; 12(10). PMID: 29016607    Free PMC article.
Highly Cited.
Risk factors and histopathological features of breast cancer among women with different menopausal status and age at diagnosis.
Ozan Unlu, Dilara Kiyak, +7 authors, Kadri Altundag.
J BUON, 2017 Apr 04; 22(1). PMID: 28365953
Epidemiology and prognosis of breast cancer in young women.
Hussein A Assi, Katia E Khoury, +3 authors, Nagi S El Saghir.
J Thorac Dis, 2013 Jul 03; 5 Suppl 1. PMID: 23819024    Free PMC article.
Highly Cited.
Breast cancer.
Nadia Harbeck, Michael Gnant.
Lancet, 2016 Nov 21; 389(10074). PMID: 27865536
Highly Cited. Review.
Breast cancer in women aging 35 years old and younger: The Egyptian National Cancer Institute (NCI) experience.
A D Darwish, A M Helal, +2 authors, A Amin.
Breast, 2016 Oct 25; 31. PMID: 27771499
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
Diana Lüftner, Ingo Bauerfeind, +21 authors, Marc Thill.
Breast Care (Basel), 2019 Dec 05; 14(5). PMID: 31798392    Free PMC article.
Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Martin Mutonga, Sedona Speedy, +6 authors, Cesar A Santa-Maria.
Breast Cancer Res Treat, 2019 Apr 13; 176(1). PMID: 30977026